Tuniu Corporation (NASDAQ:TOUR)
Tuniu Corporation operates as an online leisure travel company in China. The Company provides packaged tours, organized tours, self-guided tours and other travel related products and services. Its online platform consists of its tuniu.com Website and mobile platform. Tuniu Corporation is headquartered in Nanjing, the People’s Republic of China.
Tuniu Corporation (NASDAQ:TOUR)’s Financial Overview
Tuniu Corporation (NASDAQ) surged 4.11% yesterday to close its trading session at $5.32. The company has 1 year Price Target of $7.22. Tuniu Corporation has 52-Week high of $8.73 and 52-Week Low of $4.35. The stock touched its 52-Week High on 8.85 and 52-Week Low on 4.35. The stock traded with the volume of 229367 shares yesterday. The firm shows the market capitalization of $618.29 Million.
Tuniu Corporation (NASDAQ) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $0.1/share against the analyst consensus estimate of $0.15/share. The difference between the actual and expected EPS is $-0.05 a share with a surprise factor of -33.3%.
The firm is trading with SMA20 of 6.3 Percent, SMA50 of -5.85 Percent and SMA200 of -21.46 percent. Tuniu Corporation has P/S value of 1.87 while its P/B value stands at 1.31. Similarly, the company has Return on Assets of -4.6 percent, Return on Equity of -8.9 percent and Return on Investment of -25 Percent. The company shows Gross Margin and Operating Margin of 50.9 percent and -20.8 percent respectively.
The Stock currently has Analyst’ mean Recommendation of 2.7 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 2 analysts offering 12-month price forecasts for Tuniu Corp have a median target of 6.79, with a high estimate of 7.18 and a low estimate of 6.40. The median estimate represents a +27.63% increase from the last price of 5.32.
Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)
Cumberland Pharmaceuticals, Inc., headquartered in Nashville, Tennessee, is a specialty pharmaceutical company focused on acquiring, developing, and commercializing branded prescription products for the acute care and gastroenterology markets. The company’s lead product candidate, Amelior, which is in phase III clinical trials, is an intravenous formulation of ibuprofen for the treatment of both pain and fever. Its products also comprise Acetadote, an intravenous formulation of N-acetylcysteine for the treatment of acetaminophen poisoning; and Kristalose, a prescription laxative product, which is a crystalline form of lactulose to enhance patient acceptance and compliance. In addition, the company is developing a treatment for fluid buildup in the lungs of cancer patients and an anti-infective for treating fungal infections in immuno-compromised patients.
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)’s Financial Outlook
The 1 analysts offering 12-month price forecasts for Cumberland Pharmaceuticals Inc have a median target of 10.00, with a high estimate of 10.00 and a low estimate of 10.00. The median estimate represents a +60.00% increase from the last price of 6.25.
Cumberland Pharmaceuticals Inc. is estimated to report earnings on 03/05/2019. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.16. The reported EPS for the same quarter last year was $0.01.
According to Zacks Investment Research, Cumberland Pharmaceuticals Inc. has a Consensus Recommendation of 1. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock surged 2.29% and closed its last trading session at $6.25. The company has the market capitalization of $94.88 Million. The stock has 52-week high of $7.29 and 52-Week low of $5.06. The firm touched its 52-Week high on 7.29 and 52-Week low on 5.06. The company has volume of 2917 shares. The company has a total of 15.18 Million shares outstanding.
Cumberland Pharmaceuticals Inc. (NASDAQ) in the last quarter reported its actual EPS of $-0.05/share where the analyst estimated EPS was $-0.19/share. The difference between the actual and Estimated EPS is $0.14. This shows a surprise factor of 73.7 percent.
The company has YTD performance of 3.65 percent. Beta for Cumberland Pharmaceuticals Inc. stands at 0.44 while its ATR (average true range) is 0.5. The company has Weekly Volatility of 6.20%% and Monthly Volatility of 9.38%%.
Cumberland Pharmaceuticals Inc. has distance from 20-day Simple Moving Average (SMA20) of 0.95%, Distance from 50-Day Simple Moving Average of 1.42 percent and Distance from 200-Day Simple Moving Average of 3.14%.
The Company currently has ROA (Return on Assets) of -6.1 percent, Return on Equity (ROE) of -9.1 Percent and Return on Investment (ROI) of -11.3% with Gross margin of 82.9 percent and Operating & Profit margin of -15.5% and -14.3% respectively.